Efficacy of antiviral treatment on intrahepatic HBV DNA and histology in HBeAg -positive chronic hepatitis B patients.
- Author:
Hai-ying LU
1
;
Li-wei ZHUANG
;
Yan-yan YU
;
Chong-wen SI
;
Jian-jun ZHENG
;
Xin-yue CHEN
;
Zhong-hou HAN
;
Yong CHEN
Author Information
- Publication Type:Clinical Trial
- MeSH: Adolescent; Adult; Antiviral Agents; pharmacology; therapeutic use; DNA, Viral; blood; metabolism; Drug Therapy, Combination; Female; Hepatitis B e Antigens; immunology; metabolism; Hepatitis B, Chronic; drug therapy; immunology; pathology; virology; Humans; Interferon-alpha; pharmacology; therapeutic use; Lamivudine; pharmacology; therapeutic use; Liver; drug effects; metabolism; pathology; virology; Male; Middle Aged; Time Factors
- From: Chinese Journal of Experimental and Clinical Virology 2008;22(1):54-56
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the effect of antiviral agents on intrahepatic HBV DNA and histology in HBeAg-positive chronic hepatitis B patients.
METHODSThirty-five patients were treated with lamivudine, 16 with interferon alfa (INF-alpha), 24 with sequential Lamivudine and INF-alpha. The total duration of therapy was 12 months. Intrahepatic HBV DNA was measured quantitatively by real-time polymerase chain reaction.
RESULTSThere was significant change in all parameters of the groups of patients at the end of treatment (P < 0.05). The patients treated with sequential treatment had slightly higher HBeAg seroconversion rate (38.1%) than that of the other patients (P=0.1352). The baseline levels of intrahepatic HBV DNA in the patients with HBeAg seroconversion or undetectable serum HBV DNA were significantly lower than that of the other patients (P < 0.05).
CONCLUSIONAntiviral agents could effectively inhibit intrahepatic HBV DNA and improve hepatic histology. The patients with low baseline intrahepatic HBV DNA level may achieve better antiviral efficacy. Sequential treatment might produce high HBeAg seroconversion rate.
